Ami Vaidya, MD
Critical Care Medicine · Conway, SCNPI 1346534773
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 231 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by GSK at 32.5% of the total. Reporting peaked in 2019 at $1,807 and has fallen 70.5% since, to $532 in 2025.
Across 231 payments — averaging $15.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$598
- Boehringer Ingelheim$294
- Mylan Specialty L.p.$285
- Genentech USA, Inc.$263
- Regeneron Healthcare Solutions, Inc.$161
- plus $849 from 17 others
What the payments were for
- Food & beverage$3,628100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 93 | $1,179 |
| AstraZeneca | 34 | $598 |
| Boehringer Ingelheim | 16 | $294 |
| Mylan Specialty L.p. | 17 | $285 |
| Genentech USA, Inc. | 17 | $263 |
| Regeneron Healthcare Solutions, Inc. | 6 | $161 |
| Electromed, Inc. | 10 | $160 |
| Insmed, Inc. | 6 | $127 |
| Philips North America LLC | 5 | $85 |
| Novartis | 3 | $67 |
| Jazz Pharmaceuticals Inc. | 3 | $64 |
| Shire North American Group Inc | 3 | $42 |
| Sunovion Pharmaceuticals Inc. | 4 | $40 |
| Verona Pharma, Inc. | 2 | $36 |
| Actelion Pharmaceuticals US, Inc. | 1 | $35 |
| Merck | 1 | $33 |
| Sanofi | 2 | $30 |
| Grifols USA, LLC | 2 | $29 |
| Teva Pharmaceuticals USA, Inc. | 2 | $28 |
| Baxter Healthcare | 1 | $21 |
| Viatris Specialty LLC | 1 | $20 |
| Amgen | 1 | $17 |
| Mallinckrodt Hospital Products Inc. | 1 | $15 |
How this compares
$3,628 in reported general payments places this provider in the 75th percentile of 93 critical care medicine providers in South Carolina.
See all critical care medicine providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 452 | $385,566 |
| Breo ElliptaFluticasone/Vilanterol | 162 | $81,190 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 99 | $76,306 |
| Spiriva RespimatTiotropium Bromide | 47 | $46,770 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 92 | $45,127 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 48 | $32,006 |
| SymbicortBudesonide/Formoterol Fumarate | 79 | $24,166 |
| Advair HfaFluticasone Propion/Salmeterol | 42 | $19,648 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 812 | $19,542 |
| Incruse ElliptaUmeclidinium Bromide | 37 | $15,186 |
| Wixela InhubFluticasone Propion/Salmeterol | 54 | $9,477 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 61 | $7,487 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 27 | $4,776 |
| Ventolin HfaAlbuterol Sulfate | 22 | $2,946 |
| Montelukast Sodium | 215 | $1,959 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $1,179 | $527,069743 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $598 | $100,472178 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $294 | $78,77695 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 93 critical care medicine providers in South Carolina.
Other critical care medicine in Conway
- Hafez HayekConway$138K
- Snigdha SharmaConway$5K
- Charlton StrangeCharleston$205K
- William AlleyneRock Hill$199K
- Rahul ArgulaCharleston$186K
- James CarswellCharleston$159K
- Daniel HerrHilton Head Island$151K
- Nicholas FoxCharleston$88K
- Nasir AwanGreenville$54K
- Christopher GilbertCharleston$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.